Skip to main content
Erschienen in: Abdominal Radiology 9/2019

26.06.2019 | Perspective

Lost in translation: lessons learned from the “demise” of MRSI of the prostate

verfasst von: Antonio C. Westphalen

Erschienen in: Abdominal Radiology | Ausgabe 9/2019

Einloggen, um Zugang zu erhalten

Abstract

At times, technologies fail for reasons other than an inability to deliver on their promises. The iconic Blackberry, for example, was once coined “Research in Motion”, sold tens of millions of units, and then “disappeared” from the market because it did not accompany the new trends in design. Promising technologies may also “disappear” in the medical field. What follows is the tale of the rise and fall of proton magnetic resonance spectroscopic imaging (1H MRSI) of the prostate.
Literatur
1.
Zurück zum Zitat Cornel EB, Smits GA, Oosterhof GO, Karthaus HF, Deburyne FM, Schalken JA, et al. Characterization of human prostate cancer, benign prostatic hyperplasia and normal prostate by in vitro 1H and 31P magnetic resonance spectroscopy. J Urol. 1993;150:2019-24.CrossRefPubMed Cornel EB, Smits GA, Oosterhof GO, Karthaus HF, Deburyne FM, Schalken JA, et al. Characterization of human prostate cancer, benign prostatic hyperplasia and normal prostate by in vitro 1H and 31P magnetic resonance spectroscopy. J Urol. 1993;150:2019-24.CrossRefPubMed
2.
Zurück zum Zitat Kurhanewicz J, Dahiya R, Macdonald JM, Chang LH, James TL, Narayan P. Citrate alterations in primary and metastatic human prostatic adenocarcinomas: 1H magnetic resonance spectroscopy and biochemical study. Magn Reson Med. 1993;29:149-57.CrossRefPubMed Kurhanewicz J, Dahiya R, Macdonald JM, Chang LH, James TL, Narayan P. Citrate alterations in primary and metastatic human prostatic adenocarcinomas: 1H magnetic resonance spectroscopy and biochemical study. Magn Reson Med. 1993;29:149-57.CrossRefPubMed
3.
Zurück zum Zitat Fowler AH, Pappas AA, Holder JC, Finkbeiner AE, Dalrymple GV, Mullins MS, et al. Differentiation of human prostate cancer from benign hypertrophy by in vitro 1H NMR. Magn Reson Med. 1992;25:140-7.CrossRefPubMed Fowler AH, Pappas AA, Holder JC, Finkbeiner AE, Dalrymple GV, Mullins MS, et al. Differentiation of human prostate cancer from benign hypertrophy by in vitro 1H NMR. Magn Reson Med. 1992;25:140-7.CrossRefPubMed
4.
Zurück zum Zitat Kurhanewicz J, Vigneron DB, Nelson SJ, Hricak H, MacDonald JM, Konety B, et al. Citrate as an in vivo marker to discriminate prostate cancer from benign prostatic hyperplasia and normal prostate peripheral zone: detection via localized proton spectroscopy. Urology. 1995;45:459-66.CrossRefPubMed Kurhanewicz J, Vigneron DB, Nelson SJ, Hricak H, MacDonald JM, Konety B, et al. Citrate as an in vivo marker to discriminate prostate cancer from benign prostatic hyperplasia and normal prostate peripheral zone: detection via localized proton spectroscopy. Urology. 1995;45:459-66.CrossRefPubMed
5.
Zurück zum Zitat Heerschap A, Jager GJ, van der Graaf M, Barentsz JO, de la Rosette JJ, Oosterhof GO, et al. In vivo proton MR spectroscopy reveals altered metabolite content in malignant prostate tissue. Anticancer Res. 1997;17:1455-60.PubMed Heerschap A, Jager GJ, van der Graaf M, Barentsz JO, de la Rosette JJ, Oosterhof GO, et al. In vivo proton MR spectroscopy reveals altered metabolite content in malignant prostate tissue. Anticancer Res. 1997;17:1455-60.PubMed
6.
Zurück zum Zitat Mazaheri Y, Shukla-Dave A, Goldman DA, Moskowitz CS, Takeda T, Reuter VE, et al. Characterization of prostate cancer with MR spectroscopic imaging and diffusion-weighted imaging at 3Tesla. Magn Reson Imaging. 2019;55:93-102.CrossRefPubMed Mazaheri Y, Shukla-Dave A, Goldman DA, Moskowitz CS, Takeda T, Reuter VE, et al. Characterization of prostate cancer with MR spectroscopic imaging and diffusion-weighted imaging at 3Tesla. Magn Reson Imaging. 2019;55:93-102.CrossRefPubMed
7.
Zurück zum Zitat Leapman MS, Wang ZJ, Behr SC, Kurhanewicz J, Zagoria RJ, Carroll PR, et al. Impact of the integration of proton magnetic resonance imaging spectroscopy to PI-RADS 2 for prediction of high grade and high stage prostate cancer. Radiol Bras. 2017;50:299-307.CrossRefPubMedPubMedCentral Leapman MS, Wang ZJ, Behr SC, Kurhanewicz J, Zagoria RJ, Carroll PR, et al. Impact of the integration of proton magnetic resonance imaging spectroscopy to PI-RADS 2 for prediction of high grade and high stage prostate cancer. Radiol Bras. 2017;50:299-307.CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Fusco R, Sansone M, Petrillo M, Setola SV, Granata V, Botti G, et al. Multiparametric MRI for prostate cancer detection: Preliminary results on quantitative analysis of dynamic contrast enhanced imaging, diffusion-weighted imaging and spectroscopy imaging. Magn Reson Imaging. 2016;34:839-45.CrossRefPubMed Fusco R, Sansone M, Petrillo M, Setola SV, Granata V, Botti G, et al. Multiparametric MRI for prostate cancer detection: Preliminary results on quantitative analysis of dynamic contrast enhanced imaging, diffusion-weighted imaging and spectroscopy imaging. Magn Reson Imaging. 2016;34:839-45.CrossRefPubMed
9.
Zurück zum Zitat Lagemaat MW, Zechmann CM, Futterer JJ, Weiland E, Lu J, Villeirs GM, et al. Reproducibility of 3D 1H MR spectroscopic imaging of the prostate at 1.5T. J Magn Reson Imaging. 2012;35:166-73. Lagemaat MW, Zechmann CM, Futterer JJ, Weiland E, Lu J, Villeirs GM, et al. Reproducibility of 3D 1H MR spectroscopic imaging of the prostate at 1.5T. J Magn Reson Imaging. 2012;35:166-73.
10.
Zurück zum Zitat Gibbs P, Tozer DJ, Liney GP, Turnbull LW. Comparison of quantitative T2 mapping and diffusion-weighted imaging in the normal and pathologic prostate. Magn Reson Med. 2001;46:1054-8.CrossRefPubMedPubMedCentral Gibbs P, Tozer DJ, Liney GP, Turnbull LW. Comparison of quantitative T2 mapping and diffusion-weighted imaging in the normal and pathologic prostate. Magn Reson Med. 2001;46:1054-8.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Gibbs P, Tozer DJ, Liney GP, Turnbull LW. Comparison of quantitative T2 mapping and diffusion-weighted imaging in the normal and pathologic prostate. Magn Reson Med. 2001;46:1054-8.CrossRefPubMed Gibbs P, Tozer DJ, Liney GP, Turnbull LW. Comparison of quantitative T2 mapping and diffusion-weighted imaging in the normal and pathologic prostate. Magn Reson Med. 2001;46:1054-8.CrossRefPubMed
12.
Zurück zum Zitat Song SK, Qu Z, Garabedian EM, Gordon JI, Milbrandt J, Ackerman JJ. Improved magnetic resonance imaging detection of prostate cancer in a transgenic mouse model. Cancer Res. 2002;62:1555-8.PubMed Song SK, Qu Z, Garabedian EM, Gordon JI, Milbrandt J, Ackerman JJ. Improved magnetic resonance imaging detection of prostate cancer in a transgenic mouse model. Cancer Res. 2002;62:1555-8.PubMed
13.
14.
Zurück zum Zitat Weinreb JC, Barentsz JO, Choyke PL, Cornud F, Haider MA, Macura KJ, et al. PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2. Eur Urol. 2016;69:16-40.CrossRefPubMed Weinreb JC, Barentsz JO, Choyke PL, Cornud F, Haider MA, Macura KJ, et al. PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2. Eur Urol. 2016;69:16-40.CrossRefPubMed
15.
Zurück zum Zitat Spilseth B, Margolis DJ, Ghai S, Patel NU, Rosenkrantz AB. Radiologists’ preferences regarding content of prostate MRI reports: a survey of the Society of Abdominal Radiology. Abdominal radiology. 2018;43:1807-12.CrossRefPubMed Spilseth B, Margolis DJ, Ghai S, Patel NU, Rosenkrantz AB. Radiologists’ preferences regarding content of prostate MRI reports: a survey of the Society of Abdominal Radiology. Abdominal radiology. 2018;43:1807-12.CrossRefPubMed
16.
Zurück zum Zitat Rosenkrantz AB, Verma S, Choyke P, Eberhardt SC, Eggener SE, Gaitonde K, et al. Prostate Magnetic Resonance Imaging and Magnetic Resonance Imaging Targeted Biopsy in Patients with a Prior Negative Biopsy: A Consensus Statement by AUA and SAR. J Urol. 2016;196:1613-8.CrossRefPubMedPubMedCentral Rosenkrantz AB, Verma S, Choyke P, Eberhardt SC, Eggener SE, Gaitonde K, et al. Prostate Magnetic Resonance Imaging and Magnetic Resonance Imaging Targeted Biopsy in Patients with a Prior Negative Biopsy: A Consensus Statement by AUA and SAR. J Urol. 2016;196:1613-8.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Bellomo G, Marcocci F, Bianchini D, Mezzenga E, D’Errico V, Menghi E, et al. MR Spectroscopy in Prostate Cancer: New Algorithms to Optimize Metabolite Quantification. PLoS One. 2016;11:e0165730.CrossRefPubMedPubMedCentral Bellomo G, Marcocci F, Bianchini D, Mezzenga E, D’Errico V, Menghi E, et al. MR Spectroscopy in Prostate Cancer: New Algorithms to Optimize Metabolite Quantification. PLoS One. 2016;11:e0165730.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Starobinets O, Simko JP, Kuchinsky K, Kornak J, Carroll PR, Greene KL, et al. Characterization and stratification of prostate lesions based on comprehensive multiparametric MRI using detailed whole-mount histopathology as a reference standard. NMR Biomed. 2017;30. Starobinets O, Simko JP, Kuchinsky K, Kornak J, Carroll PR, Greene KL, et al. Characterization and stratification of prostate lesions based on comprehensive multiparametric MRI using detailed whole-mount histopathology as a reference standard. NMR Biomed. 2017;30.
19.
Zurück zum Zitat Steinseifer IK, van Asten JJ, Weiland E, Scheenen TW, Maas MC, Heerschap A. Improved volume selective (1) H MR spectroscopic imaging of the prostate with gradient offset independent adiabaticity pulses at 3 tesla. Magn Reson Med. 2015;74:915-24.CrossRefPubMed Steinseifer IK, van Asten JJ, Weiland E, Scheenen TW, Maas MC, Heerschap A. Improved volume selective (1) H MR spectroscopic imaging of the prostate with gradient offset independent adiabaticity pulses at 3 tesla. Magn Reson Med. 2015;74:915-24.CrossRefPubMed
20.
Zurück zum Zitat Tayari N, Steinseifer IK, Selnaes KM, Bathen TF, Maas MC, Heerschap A. High-Quality 3-Dimensional 1H Magnetic Resonance Spectroscopic Imaging of the Prostate Without Endorectal Receive Coil Using A Semi-LASER Sequence. Invest Radiol. 2017;52:640-6.CrossRefPubMed Tayari N, Steinseifer IK, Selnaes KM, Bathen TF, Maas MC, Heerschap A. High-Quality 3-Dimensional 1H Magnetic Resonance Spectroscopic Imaging of the Prostate Without Endorectal Receive Coil Using A Semi-LASER Sequence. Invest Radiol. 2017;52:640-6.CrossRefPubMed
21.
Zurück zum Zitat Smith CP, Harmon SA, Barrett T, Bittencourt LK, Law YM, Shebel H, et al. Intra- and interreader reproducibility of PI-RADSv2: A multireader study. J Magn Reson Imaging. 2019;49:1694-703.CrossRefPubMed Smith CP, Harmon SA, Barrett T, Bittencourt LK, Law YM, Shebel H, et al. Intra- and interreader reproducibility of PI-RADSv2: A multireader study. J Magn Reson Imaging. 2019;49:1694-703.CrossRefPubMed
Metadaten
Titel
Lost in translation: lessons learned from the “demise” of MRSI of the prostate
verfasst von
Antonio C. Westphalen
Publikationsdatum
26.06.2019
Verlag
Springer US
Erschienen in
Abdominal Radiology / Ausgabe 9/2019
Print ISSN: 2366-004X
Elektronische ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-019-02114-z

Weitere Artikel der Ausgabe 9/2019

Abdominal Radiology 9/2019 Zur Ausgabe

Letter to the Editor

Letter to the editor

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.